BeyondSpring completes sale of BeyondSpring Ltd. to Biolin Investment

BeyondSpring Inc. disclosed in an 8-K dated October 6, 2026 that it closed a Share Purchase and Collaboration Agreement on September 30, 2026. The company completed the sale of the entire issued share capital in BeyondSpring Ltd., a British Virgin Islands company and direct wholly owned subsidiary that indirectly holds interests in Dalian Wanchunbulin Pharmaceuticals Ltd., to Biolin Investment Limited, a Hong Kong company.¹

In exchange for the sale, BeyondSpring received noncash consideration consisting of a license to use data from the DUBLIN-4 clinical trial and the investor's commitment to fund Bulin's conduct of the trial and delivery of that data.¹ The collaboration covers the China portion of DUBLIN-4, a global Phase 3 trial of Plinabulin combined with docetaxel in patients with advanced or metastatic non-squamous non-small cell lung cancer lacking actionable genomic alterations whose disease progressed after prior anti-PD-(L)1 antibody therapy and platinum-based chemotherapy.¹ No cash consideration was paid or payable by the investor to the company at closing.¹

Over a three-year enrollment period following closing, Bulin must use commercially reasonable efforts to hit a specified patient-enrollment target; if that target is missed, the investor must return a portion of the acquired equity, up to 100% if the shortfall reaches 90% or more.¹

After the sale, BeyondSpring retained one common share of SEED Therapeutics and Series A-1 preferred shares representing about 29% of SEED's voting power on an as-converted basis, along with rights to elect two Series A-1 directors, though these retained interests do not give the company control over SEED.¹

According to the pro forma filing, the preliminary pro forma gain on disposition was calculated at $53,677 thousand¹, though the company cautioned the estimated gain is preliminary and the final figure may differ materially.¹